Cell Therapeutics (CTIC) jumps 21% after its Opaxio drug for treating malignant brain cancer...

|About: CTI BioPharma Corp. (CTIC)|By:, SA News Editor

Cell Therapeutics (CTIC) jumps 21% after its Opaxio drug for treating malignant brain cancer receives the FDA's orphan-drug status, which provides the developing company with marketing, fee and tax benefits. The agency assigns the status based on the early results of a Phase II study. (PR)